In this study, we report the efficacy and safety results in a subgroup analysis from the phase Ib study of patients with HR+, HER2− advanced breast cancer who received gedatolisib, palbociclib, and letrozole as their first-line treatment for advanced disease. This evidence concerns the gene ERBB2 and breast carcinoma.